Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
OKYO Pharma inks collaboration with Tufts Medical Center
OKYO Pharma begins OK-101 phase 2 dosing
OKYO Pharma to address key conference with data on dry eye drug
OKYO Pharma screens first patient for dry eye disease trial
OKYO Pharma ready to kick off dry eye trial in the US
OKYO Pharma plans UK de-listing in favour of US quote
OKYO Pharma shares soar on news it is gearing up for dry eye disease treatment trial
Why Is Okyo Pharma (OKYO) Stock Up 13% Today?
OKYO Pharma starts trial process for dry eye disease treatment
Why Is OKYO Pharma (OKYO) Stock Down 10% Today?
Why Is OKYO Pharma (OKYO) Stock Down 31% Today?
OKYO Pharma making final preparations for upcoming clinical trial of dry eye disease drug
OKYO Pharma appoints leading US ophthalmology expert to its scientific board
Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
OKYO Pharma eyes progress for OK-101 in 2023, releases interim results
OKYO Pharma receives US FDA license to start Phase 2 study
OKYO Pharma applies for the go ahead for phase II trial of its dry eye disease treatment
OKYO Pharma to work with AmbioPharm on dry eye IND filing
Okyo Pharma to focus on dry eye treatment in coming year
Okyo Pharma successfully closes US$2.5mln US fundraise
OKYO Pharma to raise US$2.5mln in the US
OKYO Pharma: Developer Of Next Generation Ocular Therapeutics
OKYO Pharma receives US patent for dry eye disease drug covering neuropathic pain
OKYO Pharma receives US regulatory approval to take dry disease candidate directly into a phase II trial
OKYO Pharma confirms OK-101 timeline
OKYO Pharma reconfirms OK-101 timeline
OKYO Pharma's lead asset receives US patent protection covering its use in dry eye disease
OKYO Pharma: Preclinical data points to ‘potent' ocular pain reducing property of its lead drug
OKYO to know if its lead asset is a success 2023
OKYO Pharma anticipates new investigational new drug filing next year
OKYO Pharma is looking to take its dry eye disease treatment straight into phase II clinical trials
OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting
OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting
OKYO Pharma working towards IND filing for dry eye treatment
("OKYO" or the "Company") - OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications
OKYO Pharma appoints contract research specialist to help advance dry eye treatment
OKYO Pharma appoints contract research specialist to help it advance its dry eye treatment
OKYO Pharma unveils promising pre-clinical data for neuropathic ocular pain drug
("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
OKYO Pharma appoints chief scientific officer
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer